

CITATION REPORT

List of articles citing

Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study

DOI: 10.1164/rccm.202006-2618oc

American Journal of Respiratory and Critical Care Medicine, 2021, 203, 553-564.

Source: <https://exaly.com/paper-pdf/77854686/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
74	Reigniting the TORCH: Chronic Obstructive Pulmonary Disease Mortality and Inhaled Corticosteroids Revisited. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 , 203, 531-532	10.2	3
73	Considerations for and Mechanisms of Adjunct Therapy in COPD. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	1
72	Triple-Therapy Trials for Chronic Obstructive Pulmonary Disease: Methodological Considerations in the Mortality Effect. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 , 203, 925-926	10.2	
71	[Chronic obstructive pulmonary disease: the right treatment for the right patient]. <i>Der Internist</i> , 2021 , 62, 679-685	0	0
70	Mortality in ETHOS: A Question of "Power". <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 , 203, 926-927	10.2	2
69	Reply to Lpez-Campos : Triple-Therapy Trials for Chronic Obstructive Pulmonary Disease: Methodological Considerations in the Mortality Effect. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 , 203, 928-929	10.2	0
68	Reply to Lpez-Campos and to Rogliani and Calzetta. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 , 203, 927-928	10.2	
67	A Cohort Study to Evaluate the Risk of Hospitalisation for Congestive Heart Failure Associated with the Use of Aclidinium and Other Chronic Obstructive Pulmonary Disease Medications in the UK Clinical Practice Research Datalink. <i>International Journal of COPD</i> , 2021 , 16, 1461-1475	3	0
66	[Pharmacological treatment optimisation in patients with stale COPD. Position of the French-language Respiratory Society. 2021 Update]. <i>Revue Des Maladies Respiratoires</i> , 2021 , 38, 539-561 ⁰		3
65	Factors Associated With Nonreceipt of Recommended COPD Medications: A Population Study. <i>Chest</i> , 2021 , 160, 1670-1680	5.3	
64	Triple versus LAMA/LABA combination therapy for patients with COPD: a systematic review and meta-analysis. <i>Respiratory Research</i> , 2021 , 22, 183	7.3	3
63	Functional respiratory imaging assessment of budesonide/glycopyrrolate/formoterol fumarate and glycopyrrolate/formoterol fumarate metered dose inhalers in patients with COPD: the value of inhaled corticosteroids. <i>Respiratory Research</i> , 2021 , 22, 191	7.3	1
62	Perplexing mortality data from triple therapy trials in COPD. <i>Lancet Respiratory Medicine</i> , 2021 , 9, 684-685	35.1	6
61	Budesonide/Glycopyrrolate/Formoterol Fumarate Co-suspension Metered Dose Inhaler: A Triple Therapy for the Treatment of Chronic Obstructive Pulmonary Disease. <i>Annals of Pharmacotherapy</i> , 2021 , 10600280211038353	2.9	
60	Benefits of budesonide/glycopyrrolate/formoterol fumarate (BGF) on symptoms and quality of life in patients with COPD in the ETHOS trial. <i>Respiratory Medicine</i> , 2021 , 185, 106509	4.6	5
59	Budesonide/Glycopyrronium/Formoterol: A Review in COPD. <i>Drugs</i> , 2021 , 81, 1411-1422	12.1	3
58	CONQUEST Quality Standards: For the Collaboration on Quality Improvement Initiative for Achieving Excellence in Standards of COPD Care. <i>International Journal of COPD</i> , 2021 , 16, 2301-2322	3	2

57	Inhaled Dual Phosphodiesterase 3/4 Inhibitors for the Treatment of Patients with COPD: A Short Review. <i>International Journal of COPD</i> , 2021 , 16, 2363-2373	3	2
56	Triple Therapy in COPD: Time for Adaptive Selection Trials. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2021 , 1-5	2	1
55	Triple Inhaler versus Dual Bronchodilator Therapy in COPD: Real-World Effectiveness on Mortality. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2021 , 1-9	2	3
54	Fractal dimension in CT low attenuation areas is predictive of long-term oxygen therapy initiation in COPD patients: Results from two observational cohort studies. <i>Respiratory Investigation</i> , 2021 , 60, 137-137	3.4	
53	Perplexing mortality data from triple therapy trials in COPD - Author's reply. <i>Lancet Respiratory Medicine</i> , 2021 , 9, e96	35.1	0
52	Journal Club: Do Inhaled Corticosteroids Reduce All-Cause Mortality in Chronic Obstructive Pulmonary Disease? What is the Latest Evidence?. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2021 , 8, 1-3	2.7	
51	Improvements in lung function with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler dual therapies in patients with COPD: a sub-study of the ETHOS trial. <i>Therapeutic Advances in Respiratory Disease</i> , 2021 , 15, 17534666211034329	4.9	3
50	A scintigraphy study of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler in patients with moderate-to-very severe chronic obstructive pulmonary disease. <i>Respiratory Research</i> , 2021 , 22, 261	7.3	1
49	Designing Clinical Trials in "Regular" COPD Versus Alpha-1 Antitrypsin Deficiency-Associated COPD: "More Alike than Unalike?". <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2021 ,	2.7	
48	Beyond Dual Bronchodilation - Triple Therapy, When and Why.. <i>International Journal of COPD</i> , 2022 , 17, 165-180	3	2
47	Evaluating the Impact of Triple Therapy on Mortality in Copd: The End is the Beginning?. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2022 , 1-4	2	
46	Trends in non-receipt of recommended COPD medication.. <i>ERJ Open Research</i> , 2022 , 8,	3.5	
45	A Pooled Analysis of Mortality in Patients with COPD Receiving Dual Bronchodilation with and without Additional Inhaled Corticosteroid.. <i>International Journal of COPD</i> , 2022 , 17, 545-558	3	3
44	Fluticasone-Based versus Budesonide-Based Triple Therapies in COPD: Real-World Comparative Effectiveness and Safety.. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2022 , 19, 109-117	2	
43	COPD - do the right thing.. <i>BMC Family Practice</i> , 2021 , 22, 244	2.6	5
42	Chronic obstructive pulmonary disease and atherosclerosis: common mechanisms and novel therapeutics.. <i>Clinical Science</i> , 2022 , 136, 405-423	6.5	1
41	Screening for Chronic Obstructive Pulmonary Disease: Challenges and Opportunities.. <i>JAMA - Journal of the American Medical Association</i> , 2022 , 327, 1768-1770	27.4	0
40	Relationship between prior inhaled corticosteroid use and benefits of budesonide/glycopyrronium/formoterol fumarate dihydrate on exacerbations, symptoms, health-related quality of life, and lung function in patients with chronic obstructive pulmonary disease: Analyses from the ETHOS study. <i>Respiratory Medicine</i> , 2022 , 187, 106857	4.6	0

39	Advances in inhaled corticosteroids for the treatment of chronic obstructive pulmonary disease: what is their value today?. <i>Expert Opinion on Pharmacotherapy</i> , 2022 ,	4	0
38	Lack of Association between Inhaled Corticosteroid Use and the Risk of Future Exacerbation in Patients with GOLD Group A Chronic Obstructive Pulmonary Disease. <i>Journal of Personalized Medicine</i> , 2022 , 12, 916	3.6	
37	Relationship between risk, cumulative burden of exacerbations and mortality in patients with COPD: modelling analysis using data from the ETHOS study. <i>BMC Medical Research Methodology</i> , 2022 , 22,	4.7	1
36	Blood Eosinophils and Chronic Obstructive Pulmonary Disease: A GOLD Science Committee 2022 Review. <i>American Journal of Respiratory and Critical Care Medicine</i> ,	10.2	7
35	Clinical characteristics, treatment persistence and outcomes among patients with COPD treated with single- or multiple-inhaler triple therapy: a retrospective analysis in Spain. <i>Chest</i> , 2022 ,	5.3	0
34	Computertomographie bei chronisch-obstruktiver Lungenerkrankung.		0
33	Pharmacotherapy and Mortality in COPD.		1
32	Chronic hypercapnic respiratory failure and non-invasive ventilation in people with chronic obstructive pulmonary disease. 2022 , 1, e000146		
31	Comparing the Efficacy and Safety Profile of Triple Fixed-Dose Combinations in COPD: A Meta-Analysis and IBiS Score. 2022 , 11, 4491		0
30	Forecast of the socioeconomic burden of COPD in the Russian Federation in 2022. 2022 , 32, 507-516		0
29	Association of COPD exacerbations and acute cardiovascular events: a systematic review and meta-analysis. 2022 , 16, 175346662211136		0
28	Single-Inhaler Triple versus Dual Bronchodilator Therapy in COPD: Real-World Comparative Effectiveness and Safety. Volume 17, 1975-1986		0
27	Different inhaled corticosteroid doses in triple therapy for chronic obstructive pulmonary disease: systematic review and Bayesian network meta-analysis. 2022 , 12,		0
26	May a different kinetic mode explain the high efficacy/safety profile of inhaled budesonide?. 2022 , 77, 102167		0
25	Association of coronary artery calcification with clinical and physiological characteristics in patients with COPD: Results from COSYCONET. 2022 , 204, 107014		0
24	Prompt initiation of triple therapy following hospitalization for a chronic obstructive pulmonary disease exacerbation in the United States: An analysis of the PRIMUS study. 2022 , 28, 1366-1377		0
23	Letter to the editor in response to the article Yang M, Li Y, Jiang Y, Guo S, He JQ, Sin DD. Combination therapy with long-acting bronchodilators and the risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. <i>Eur Respir J</i> . 2022 Sep 22 :2200302. 2202208		0
22	COPD: Providing the right treatment for the right patient at the right time. 2022 , 107041		0

21	Benefits of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate on COPD Exacerbations, Lung Function, Symptoms, and Quality of Life Across Blood Eosinophil Ranges: A Post-Hoc Analysis of Data from ETHOS. Volume 17, 3061-3073	○
20	Effectiveness of Extrafine Single Inhaler Triple Therapy in Chronic Obstructive Pulmonary Disease (COPD) in Germany [The TriOptimize Study. Volume 17, 3019-3031	○
19	Actualité concernant la prise en charge médicamenteuse de la BPCO. 2022 , 14, 2S398-2S403	○
18	Biologic therapies for chronic obstructive pulmonary disease. 1-11	○
17	Inhaled Corticosteroids and COPD. 2023 , 163, 8-9	○
16	PROMETHEUS: Long-Term Exacerbation and Mortality Benefits of Implementing Single-Inhaler Triple Therapy in the US COPD Population. 2023 , 10,	○
15	PROMETHEUS: Long-Term Exacerbation and Mortality Benefits of Implementing Single-Inhaler Triple Therapy in the US COPD Population.	○
14	Practical Recommendations for a Selection of Inhaled Corticosteroids in COPD: A Composite ICO Chart. 2023 , 13, 213	○
13	Managing chronic obstructive pulmonary diseases in 2023 [What is new?. 2023 , 0	○
12	Triple therapy in COPD: understanding the data. 2023 , 9, 00615-2022	○
11	CC16 augmentation reduces exaggerated COPD-like disease in Cc16-deficient mice. 2023 , 8,	○
10	Standardized airway wall thickness Pi10 from routine CT scans of COPD patients as imaging biomarker for disease severity, lung function decline, and mortality. 2023 , 17, 175346662211486	○
9	Reducing the Risk of Mortality in Chronic Obstructive Pulmonary Disease With Pharmacotherapy: A Narrative Review. 2023 , 98, 301-315	1
8	Infección bronquial crónica en EPOC estable. 2023 , 5, 100234	○
7	Inhaled therapy, cardiovascular risk and benefit—risk considerations in COPD: innocent until proven guilty, or vice versa?. 2023 , 61, 2202135	○
6	El eje cardiopulmonar y la mortalidad cardiovascular en el paciente EPOC. 2023 , 49, 101928	○
5	Comorbid conditions as predictors of mortality in severe COPD [An eight-year follow-up cohort study. 2023 , 10,	○
4	Pathophysiology, Therapeutic Targets, and Future Therapeutic Alternatives in COPD: Focus on the Importance of the Cholinergic System. 2023 , 13, 476	○

- 3 Impact of triple therapy on mortality in COPD. **2023**, 19, 220260 ○
- 2 Exacerbations Predict Severe Cardiovascular Events in Patients with COPD and Stable Cardiovascular Disease: A Nationwide, Population-Based Cohort Study. Volume 18, 419-429 ○
- 1 High versus Medium Dose of Inhaled Corticosteroid in Chronic Obstructive Lung Disease: A Systematic Review and Meta-Analysis. Volume 18, 469-482 ○